Long-term treatment with carbamazepine affects CSF somatostatin immunoreactivity in epileptic patients.
A number of pharmacological evidence supports the view that somatostatin (SS) may be importantly involved in the seizure susceptibility both in humans and in laboratory animals. In a previous report the Authors have provided the finding that a short-term carbamazepine (CBZ) administration is able to reduce SS-CSF-IR in epileptic patients. The present study has been carried out to investigate whether a long-term treatment with CBZ affects in a similar way SS-IR content in CSF from temporal lobe epileptics (CPS). The results confirm and expand previous evidence suggesting that CBZ lowering effect on CSF-SS-IR may be relevant to its anticonvulsivant action.
Steardo
L
L
Center of Neuropharmacology, University of Milan.
Testa
N
N
Perez
J
J
Attanasio
A
A
Sorge
F
F
Steardo
M R
MR
Biondi
A
A
D002220:Carbamazepine / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D002555:Cerebrospinal Fluid / Q000187:drug effects; D003864:Depression, Chemical; D017029:Epilepsy, Complex Partial / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D013004:Somatostatin / Q000134:cerebrospinal fluid*
D002220:Carbamazepine; D013004:Somatostatin